Willemijn Rijnink

Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

F. Krammer, Ying K. Tam, M. McMahon, 2022, Nature Communications.

B-Cells and Antibodies as Contributors to Effector Immune Responses in Tuberculosis

T. Ottenhoff, S. Joosten, Willemijn Rijnink, 2021, Frontiers in Immunology.

SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2

H. van Bakel, Julian Q. Zhou, V. Simon, 2021, Cell.

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing antibodies and targets both the NTD and the RBD

H. van Bakel, Julian Q. Zhou, V. Simon, 2021, medRxiv.

Assessment of a quadrivalent nucleoside-modified mRNA vaccine that protects against group 2 influenza viruses

A. Sárközy, M. Kanekiyo, B. Graham, 2022, Proceedings of the National Academy of Sciences of the United States of America.

The plasmablast response to SARS-CoV-2 mRNA vaccination is dominated by non-neutralizing 1 antibodies and targets both the NTD and the RBD 2

F. Krammer, G. Bajic, A. Ellebedy, 2021 .